+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030- Product Image
Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030- Product Image
Sale

Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013888
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antithrombotic Drugs Market grew from USD 42.47 billion in 2024 to USD 45.15 billion in 2025. It is expected to continue growing at a CAGR of 6.06%, reaching USD 60.49 billion by 2030.

A New Era Unveiled in Antithrombotic Therapies

Antithrombotic therapies stand at the vanguard of cardiovascular care, offering life-saving prevention against thromboembolic events that affect millions globally each year. As therapeutic modalities continue to evolve, understanding the convergence of clinical innovation, regulatory shifts, and market dynamics has never been more critical. This executive summary distills the most salient developments shaping antithrombotic drugs, providing decision-makers with a synthesized view of emerging trends and strategic considerations.

Drawing upon extensive engagement with clinical experts, industry leaders, and end-users, this overview frames the antithrombotic landscape in its full complexity. From the rise of novel direct oral anticoagulants to the integration of digital health monitoring, each advancement carries implications for product positioning, patient outcomes, and competitive differentiation. Forward-thinking organizations must navigate these transformative forces with clarity and agility, leveraging data-driven insights to inform strategic planning and investment priorities.

Shifting Currents Reshaping Antithrombotic Care

In recent years, the antithrombotic landscape has been reshaped by a wave of transformative shifts that extend far beyond incremental formulation improvements. Precision medicine approaches now guide the selection of anticoagulant regimens tailored to individual patient risk profiles, while real-world evidence continues to refine dosing guidelines and adherence strategies. These advances coincide with evolving clinical recommendations that favor direct oral anticoagulants over traditional vitamin K antagonists in many indications, reflecting a paradigm shift toward simplified administration and enhanced safety.

Concurrently, the integration of digital health platforms has enabled remote monitoring of therapeutic response, empowering clinicians to adjust treatment in real time and mitigate adverse effects. Artificial intelligence tools are also accelerating drug discovery, forecasting patient outcomes, and identifying novel targets for antithrombotic intervention. Together, these shifts are converging to create a more dynamic and patient-centric field, where agility and innovation determine market leadership.

Tariff Tides Redefining Market Dynamics

The introduction of new tariff policies in the United States during 2025 has exerted a profound impact on antithrombotic supply chains and pricing structures. By imposing additional duties on key active pharmaceutical ingredients and finished dosage forms, manufacturers and distributors have encountered upward pressure on cost bases. These changes have necessitated a reevaluation of procurement strategies, as companies seek to mitigate margin erosion through localized production and supply chain diversification.

In response, many global stakeholders have pursued near-shoring initiatives, establishing or expanding manufacturing capabilities within tariff-exempt regions to preserve competitive pricing. Simultaneously, partnerships with contract development and manufacturing organizations have gained traction as a means to spread risk and maintain operational flexibility. Ultimately, the interplay between regulatory duty frameworks and strategic manufacturing realignments will continue to define market accessibility, particularly for high-value anticoagulant therapies.

Precision Insights Across Market Segments

Analyzing the market through the lens of drug class reveals a clear hierarchy of innovation and adoption. Anticoagulants dominate in terms of R&D investment and clinical uptake, with direct oral anticoagulants capturing the lion’s share of new prescriptions due to their favorable safety profile and ease of administration compared to traditional vitamin K antagonists. Within this category, direct thrombin inhibitors such as dabigatran have carved out a distinct niche, while factor Xa inhibitors-apixaban, edoxaban, and rivaroxaban-have each garnered strong clinician and patient preference. Heparins maintain relevance in acute care settings, where low molecular weight heparins ensure predictable pharmacokinetics and unfractionated heparin provides reversibility in high-risk procedures.

Indication-based segmentation further underscores the tailored nature of antithrombotic therapy. Atrial fibrillation remains the largest driver of anticoagulant use, with deep vein thrombosis and pulmonary embolism closely following due to rising awareness and improved diagnostic capabilities. Myocardial infarction treatment protocols increasingly incorporate antiplatelet regimens alongside anticoagulants, while stroke prevention strategies leverage both classes to reduce recurrence risks. The route of administration distinctly influences patient adherence, as oral tablets dominate chronic therapy settings and injectable formulations remain critical for acute interventions. Finally, end users span home care environments, where self-administration is paramount, to hospital settings that demand rapid onset and adjustable dosing, as well as retail pharmacies that ensure ongoing access and patient education.

Regional Frontiers Driving Future Growth

Geographic analysis highlights divergent growth trajectories and adoption patterns. In the Americas, robust healthcare infrastructure and well-established reimbursement frameworks support rapid uptake of novel therapies, while payers grapple with balancing innovation costs against long-term outcomes savings. In Europe, Middle East & Africa, heterogeneous regulatory landscapes and variable access create both opportunities and challenges for market entry, prompting manufacturers to tailor launch strategies and commercial partnerships to regional nuances. Asia-Pacific emerges as a high-potential frontier, driven by rising prevalence of cardiovascular disease, expanding hospital capacity, and growing patient awareness, even as pricing pressures and local manufacturing mandates shape competitive dynamics.

Together, these regions illustrate how economic conditions, regulatory frameworks, and healthcare delivery models converge to influence therapy adoption. Strategic planners must calibrate investments and engagement efforts to reflect each territory’s unique demand drivers, ensuring that product portfolios align with regional priorities and that access initiatives address local payer and clinician expectations.

Strategic Movements Among Leading Innovators

Leading pharmaceutical companies are advancing differentiated strategies to capture value in the antithrombotic arena. Established global players have reinforced their position through lifecycle management programs, securing additional patent protection or novel delivery formats for blockbuster products. Concurrently, agile mid-sized firms and biotechs are forging collaborations to accelerate pipeline progression, focusing on first-in-class molecules and targeted indications with unmet needs. Strategic alliances with diagnostic technology providers are also on the rise, aimed at integrating biomarker-driven patient selection into clinical practice and strengthening competitive moats.

In parallel, contract development and manufacturing organizations continue to expand their service offerings, leveraging modular production technologies and quality-by-design principles to accommodate the stringent regulatory requirements of antithrombotic drug manufacture. This ecosystem of partnerships underscores the importance of cross-sector collaboration in maintaining supply chain resilience and delivering innovative therapies to market faster. As patent cliffs approach for several high-value agents, companies are doubling down on next-generation candidates and seeking to differentiate through improved safety, convenience, and cost-effectiveness.

Actionable Roadmap for Trailblazing Leadership

To remain at the forefront of antithrombotic innovation, industry leaders must embrace a multifaceted approach that balances scientific rigor with market pragmatism. Firstly, they should prioritize adaptive clinical trial designs that incorporate digital monitoring and real-world evidence to accelerate development timelines and demonstrate value to payers. Secondly, forging deeper collaborations with diagnostic and digital health providers will enable more precise patient stratification and superior adherence support. Thirdly, regional go-to-market strategies must be refined to align with local regulatory expectations and healthcare funding models, ensuring rapid access while maintaining price sustainability.

Moreover, supply chain agility must become a core competency. Diversifying manufacturing footprints and engaging in strategic partnerships can mitigate tariff impacts and raw material risks. Finally, companies should invest in patient education initiatives and physician outreach programs that underscore the comparative benefits of novel anticoagulants, fostering trust and driving sustained adoption. Implementing these recommendations will position organizations to capture emerging opportunities and drive meaningful improvements in patient outcomes.

Methodological Rigor Underpinning Insights

This research leverages a triangulated methodology that combines quantitative data analysis with qualitative expert insights. Secondary sources include peer-reviewed journals, regulatory filings, and proprietary databases that track prescription trends and supply chain movements. Primary data were obtained through in-depth interviews with cardiologists, hematologists, payers, and procurement specialists across key markets, ensuring a comprehensive understanding of evolving treatment paradigms and decision criteria.

Rigorous validation processes were employed, including cross-referencing data points to identify discrepancies and conducting scenario analyses to test the robustness of strategic assumptions. Stakeholder workshops provided additional context on real-world challenges and opportunities, while advisory panels of industry veterans reviewed draft findings to refine interpretations. This methodological rigor underpins the reliability of the insights presented and ensures that recommendations are grounded in both empirical evidence and operational realities.

Synthesizing Perspectives for Strategic Clarity

In synthesizing the multifaceted drivers of the antithrombotic market, several core themes emerge. The shift toward direct oral anticoagulants reflects a broader trend of patient-centric care, while digital health integration accelerates the transition to data-driven decision making. Trade policy developments underscore the importance of supply chain resilience, and geographic nuances highlight the need for tailored regional playbooks. Equally, collaborative innovation models and adaptive trial frameworks are redefining how therapies advance from bench to bedside.

Together, these elements coalesce into a strategic blueprint for stakeholders seeking to navigate the complexities of antithrombotic therapy. By aligning product portfolios with clinical needs, regulatory landscapes, and payer expectations, organizations can secure sustainable growth and deliver enhanced value to patients. This executive summary provides the essential context and actionable insights needed to drive informed decision making and chart a path forward in this dynamic therapeutic domain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Anticoagulants
      • Direct Oral Anticoagulants
        • Direct Thrombin Inhibitors
          • Dabigatran
        • Factor Xa Inhibitors
          • Apixaban
          • Edoxaban
          • Rivaroxaban
      • Heparins
        • Low Molecular Weight Heparin
        • Unfractionated Heparin
      • Vitamin K Antagonists
    • Antiplatelets
    • Thrombolytics
  • Indication
    • Atrial Fibrillation
    • Deep Vein Thrombosis
    • Myocardial Infarction
    • Pulmonary Embolism
    • Stroke Prevention
  • Route Of Administration
    • Oral
      • Tablet
    • Parenteral
      • Injection
  • End User
    • Home Care
    • Hospital
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bayer Aktiengesellschaft
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Novartis AG
  • Merck & Co., Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antithrombotic Drugs Market, by Drug Class
8.1. Introduction
8.2. Anticoagulants
8.2.1. Direct Oral Anticoagulants
8.2.1.1. Direct Thrombin Inhibitors
8.2.1.1.1. Dabigatran
8.2.1.2. Factor Xa Inhibitors
8.2.1.2.1. Apixaban
8.2.1.2.2. Edoxaban
8.2.1.2.3. Rivaroxaban
8.2.2. Heparins
8.2.2.1. Low Molecular Weight Heparin
8.2.2.2. Unfractionated Heparin
8.2.3. Vitamin K Antagonists
8.3. Antiplatelets
8.4. Thrombolytics
9. Antithrombotic Drugs Market, by Indication
9.1. Introduction
9.2. Atrial Fibrillation
9.3. Deep Vein Thrombosis
9.4. Myocardial Infarction
9.5. Pulmonary Embolism
9.6. Stroke Prevention
10. Antithrombotic Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.2.1. Tablet
10.3. Parenteral
10.3.1. Injection
11. Antithrombotic Drugs Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.4. Retail Pharmacy
12. Americas Antithrombotic Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Antithrombotic Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Antithrombotic Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Bayer Aktiengesellschaft
15.3.2. Pfizer Inc.
15.3.3. Bristol-Myers Squibb Company
15.3.4. Sanofi S.A.
15.3.5. AstraZeneca PLC
15.3.6. Johnson & Johnson
15.3.7. Boehringer Ingelheim International GmbH
15.3.8. Daiichi Sankyo Company, Limited
15.3.9. Novartis AG
15.3.10. Merck & Co., Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTITHROMBOTIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTITHROMBOTIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTITHROMBOTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 144. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 169. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 170. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 173. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 176. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 177. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 188. SPAIN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 232. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 246. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 247. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 250. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 253. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 254. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 257. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 261. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 264. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 265. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 292. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 293. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 294. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 295. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 297. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 298. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 301. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 302. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 305. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 308. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 309. TURKEY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 323. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 324. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2030 (USD MILLION)
TABLE 327. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 330. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 331. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 334. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (

Companies Mentioned

The companies profiled in this Antithrombotic Drugs market report include:
  • Bayer Aktiengesellschaft
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Novartis AG
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 45.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 60.49 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antithrombotic Drugs Market 2024-2028 - Product Image

Antithrombotic Drugs Market 2024-2028

  • Report
  • 161 Pages
  • Global
From
Factor XI Inhibitors - Pipeline Insight, 2025 - Product Image

Factor XI Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Intracranial Hemorrhage - Pipeline Insight, 2025 - Product Image

Intracranial Hemorrhage - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease - Product Image

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease

  • Book
Sickle Cell Disease Treatment Market by Treatment Type, Patient Age Group, Drug Administration Method, Disease Type, End User - Global Forecast to 2030 - Product Image

Sickle Cell Disease Treatment Market by Treatment Type, Patient Age Group, Drug Administration Method, Disease Type, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From

About the Antithrombotics Market

Antithrombotics are drugs used to prevent the formation of blood clots, which can lead to cardiovascular diseases such as stroke and heart attack. These drugs work by inhibiting the activity of clotting factors in the blood, thus preventing the formation of clots. Common antithrombotics include aspirin, clopidogrel, warfarin, and heparin. Aspirin is the most widely used antithrombotic, and is often prescribed to reduce the risk of stroke and heart attack. Clopidogrel is used to prevent blood clots in patients with coronary artery disease, while warfarin is used to prevent and treat blood clots in patients with atrial fibrillation. Heparin is used to prevent and treat deep vein thrombosis and pulmonary embolism. The antithrombotics market is highly competitive, with many large pharmaceutical companies offering a range of products. Some of the major players in the market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. These companies are continuously developing new products to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.